ZymoGenetics

Early pioneer in recombinant protein-based therapeutics

Zymogenetics was a biopharmaceutical company focusing on discovery, development, and commercialization of protein-based therapeutics to treat cardiovascular, autoimmune, and viral diseases. Zymogenetics completed its IPO on NASDAQ in 2002 and was acquired by BMS in 2010.

Status

IPO in 2002; Acquired by BristolMyersSquibb in 2010

Year of Investment

2000

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Seattle, Washington